Using population-based routine data for evidence-based health policy decisions: Lessons from three examples of setting and evaluating national health policy in Australia, the UK and the USA

Journal of Public Health

Volumn 29, Issue 4, 2007, Pages 463-471

  Morrato, Elaine H ^a   Elias, Melinda ^b,c   Gericke, Christian A ^c,d,e  

^a UNIVERSITY OF COLORADO   (United States)

^b TECHNISCHE UNIVERSITÄT BERLIN   (Germany)

^c EUROPEAN OBSERVATORY ON HEALTH SYSTEMS AND POLICIES   (United Kingdom)

^d UNIVERSITY OF ADELAIDE   (Australia)

^e Department of Public Health Policy ^*  (Australia)

Author keywords

Decision making; Evaluation; Health policy; Retrospective databases; Routine databases

Indexed keywords

ARTICLE; AUSTRALIA; DRUG TOXICITY; EVALUATION; EVIDENCE BASED MEDICINE; FACTUAL DATABASE; HEALTH CARE POLICY; HOSPITAL ADMISSION; HUMAN; INFORMATION PROCESSING; MANAGEMENT; NATIONAL HEALTH SERVICE; PREVENTIVE HEALTH SERVICE; UNITED KINGDOM; UNITED STATES;

AUSTRALIA; DATA COLLECTION; DATABASES, FACTUAL; DRUG TOXICITY; EVALUATION STUDIES AS TOPIC; EVIDENCE-BASED MEDICINE; GREAT BRITAIN; HEALTH POLICY; HUMANS; IMMUNIZATION PROGRAMS; POLICY MAKING; STATE MEDICINE; UNITED STATES; WAITING LISTS;

EID: 36249027554     PISSN: 17413842     EISSN: 17413850     Source Type: Journal    
DOI: 10.1093/pubmed/fdm065     Document Type: Article

References (62)

1. Anderson LM, Brownson RC, Fullilove LT. et al. Evidence-based public health policy and practice: promises and limits. Am J Prev Med 2005;28(5S): 226-30.
2. The Cochrane Collaboration [cited May 2 2007]. Available at 〈http://www.cochra.ne.org/index.htm〉.
3. Oxford-Centre for Evidence-Based Medicine [cited May 2 2007]. Available at 〈http://wwwcebm.net/index.asp 〉.
4. The Australian Centre for Evidence Based Clinical Practice (ACEBCP) [cited May 2 2007]. Available at 〈http://www.acebcp.org.au/ 〉.
5. Clancy CM, Slutsky JR, Patton LT. Evidence-based Health Care 2004: AHRQ Moves Research to Translation and Implementation. Health Serv Res 2004;39(5): pxv-xxiv.
6. Murray J, Lopez A (eds). The Global Burden of Disease: A Comprehensive Assessment of Mortality and Disability from Diseases, Injuries, and Risk Factors in 1990 and Projected to 2020. Cambridge, MA: Harvard University Press, 1996.
7. Solesbury W Evidence Based Policy: Whence It Came and Where It's Going. Queen Mary, University of London: ESRC UK Centre for Evidence Based Policy and Practice. 2001.
8. Dobrow MJ, God V, Upshur REG. Evidence-based health policy: context and utilisation. Soc Sci Med 2004;58(1):207-17.
9. Oxford-Centre for Evidence-Based Medicine. Levels of Evidence and Grades of Recommondation 20017 [cited May 1 2007]. Available at 〈http://www.cebm.net/levels_of_evidence.asp#levls〉.
10. U.S. Preventive Services Task Force Ratings: Strength of Recommendations and Quality of Evidence. Guide to Clinical Preventive Services, Third Edition: Periodic Updates, 2000-2003, Rockville, MD: Agency for Healthcare Research and Quality.
11. Sturm R. Evidence-based health policy versus evidence-based medicine. Psychiatry Serv 2002;53(12):1499.
12. AbouZahr C, Boerma T. Health information systems: the foundations of public health. Bull World Health Organ 2005;83(8):578-83
13. Wetterhall SF, Pappaioanou M, Thacker SB. et al. The role of public-health surveillance: information for effective action in public health. Morb Mortal Wkly Rep 1992;41(12):207.
14. Australian Government and Department of Health and Ageing. History of the Immunise Australia Program. 2006 [cited. April. 24 2007]. Available at 〈http://www.immunise.health.gov.au/internet/immunise/publishing.nsf/ Content/history〉.
15. Australian Government and Department of Health and Ageing. Australian Childhood Immunization Register. 1996 [cited April 25 2007]. Available at 〈.http://www.medicareaustralia.gov.au/yourhealth/our_services/aacir. htm〉.
16. Australian Government, Australian Childhood Immunization Register Commun Dis Intell 1998;22:36-7.
17. Goldfeld S, Oberklaid F. Maintaining an agenda for children: the role of data in linking policy, politics and outcomes. Mid J Aus 2005;183(4):209-11.
18. Australian Government and Department of Health and Ageing. Immunise Australia Program: Publications. 2007 [cited April 27 2007]. Available at 〈http://www.health.gov.au/internet/immunise/publishing.nsf/Content/ publications〉.
19. Australian Government, Department of Health and Ageing, and C.D. Australia. National Notifiable Diseases Surveillance System. 2007 [cited April 26 2007]. Available at 〈http://www9.health.gov.au/cda/Source/CDA- index.cfm〉.
20. Australian Government and Department of Health and Ageing. Australian Institute of Health and Welfare (AIHW) National Hospital Morbidity Database. 2007 [cited April 28 2007]. Available at 〈http://www.aihw.gov.au/ dataonline.cfm〉.
21. Krause VI. Invasive pneumococcal disease in Australia: enhanced surveillance, lessons learned and a special focus on Northern Australia. In 9th National Immunization/1st PHAA Asia Pacific Vaccine Preventable Disease Conference. Canberra, Public Health Association of Australia, Cairns, Queensland, 2004.
22. Australian Government and Department of Health and Ageing. Immunise Australia Program: childhood pneumococcal vaccination program. 2005 [cited April 30 2007]. Available at 〈http://wwwimmunise.health. gov.au/interne/immunise/publishing.nsf/Content/pneuv-child〉.
23. McIntyre P, Kelly H, Mulholland E. Immunization at the crossroads: 9th National Immunization/ 1st Asia-Pacific Vaccine Preventable Diseases Conference. National Centre for Immunization Research: Sydney, NSW. Med J Aus 2005;182(1):15-16.
24. Australian Government, Department of Health and Ageing, and Australian Institute of Health and Welfare, A picture of Australia's children. Canberra: AIHW 2005.
25. Senator Kay Patterson and Minister for Australia's Health and Ageing Boost to Australia's national immunization program. 2003 [cited April 30 2007]. Available at 〈http://wwwhealth.gov.au/internet/wcms/publishing.n.sf/ Content/health-mediarel-yr2()03-kp-kp03205.htm〉.
26. Australian Government and Department of Health and Ageing. General Practice Immunisation Incentives (GPII) Scheme. 2007 [cited April 30 2007]. Available at 〈http://www.medicareaustralia.gov.au/providers/ incenrives_allowances/gpii_scheme.htm〉.
27. Harrison A, Appleby J. The War on Waiting for Hospital Treatment: What has Labour Achieved and What Challenges Remain? The Kings Fund, 2005.
28. Lewis R, Appleby J. Can the English NHS Meet the 18-Week Waiting List Target?, J Royal Soc Med, 2006;99:10-13.
29. Smethurst D, Williams H. Self Regulation in hospital waiting lists. J Royal Soc Med, 2000;95:287-9.
30. Audit Commission 2003 Report on Waiting for elective admission: Review of National Findings' 2003 [cited April 23 2007]. Available at 〈.http://www.audit-commission.gov.uk/Products/NATIONAL-REPORT/ C98CB150-9FF3-11d7-B304-0060085F8572/Waiting AHP.pdf〉.
31. Appleby J, Boyle S, Devlin N, Harley M, Harrison A, Locock L, Thorby R. Sustaining Reductions on Waiting Times: Identifying Successful Strategies. Final Report to the Department of Health. 2005, The Kings Fund.
32. National Health Service Modernisation Agency. The Little Wizard. 2003 [cited April 23 2007]. Available at 〈http://wwwnatpact.nhs.uk/ demand_management/wizards/little_wi.zard/NHS%20Little%20 Wizard.pdf〉.
33. Harris Interactive. The Public Has Doubts About the Pharmaceutical Industry's Willingness to Publish Safety Information about Thar Drugs in a Timely Manner. 2005 [cited May 1 2007]. Available at 〈http://www. harrisinteractive.com/news/newsletters/wsj.healthnews/WSJOnline_HI_Health- CarePoll.2005vol.4_iss01.pdf〉.
34. Institute of Medicine and Committee on the Assessment of the US Drug Safety System Board, on Population Health and Public Health Practice, The Future of Drug Safety: Promoting and Protecting the Health of the Public. Washington, DC: The National Academies Press, 2006.
35. Seligman P. Effective Risk Management: A Regulatory Perspective. 2002 [cited March 31 2004]. Available at ∠http://www.fda.gov/cder/Offices/ OPaSS/default.htm#Publications%20and/%20Presentations〉.
36. Wysowski DK, Swartz L. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions. Arch Intern Med 2005;165(12): 1363-9.
37. Murphy S, Roberts R. 'Black box' 101: How the Food and Drug Administration evaluates, communicates, and manages drug benefit/risk. J Allergy Clin Immunol 2006;117(1):34-9.
38. Wadman M. Experts call for active surveillance of drug safety. Nature 2007;446(7134):358-9.
39. Strom BL. Overview of automated databases in pharmacoepidemiology. In: Strom BL, Kimmel SE (eds). Textbook of Pharmacoepidemiology. West Sussex, England: John Wiley & Sons Ltd, 2006:167-72.
40. Stergachis A. et al. Examples of automated databases. In: Strom. BL, Kimmel SE (eds). Textbook of Pharmacoepidemiology. West Sussex, England: John Wiley & Sons Ltd, 2006.
41. U.S. Food and Drug Administration. FDA Awards Contracts on Databases of Adverse Effects of Marketed Drugs Ability to Monitor Approved Drugs Enhanced. 2005 [cited April 30 2007]. Available at 〈http://www.fda.gov/ bbs/topics/answers/2005/ans01368.html〉.
42. International Society for Pharmacoeconomics and Outcomes Research, ISPOR. Digest of International Databases. 2007 [cited April 30 2007]. Available at 〈http://wwwispor.org/Intl_Databases/ind.ex.asp〉.
43. Graham DJ. et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cydo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet 2005;365(9458):475-81.
44. Wang PS. et al. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med 2005;353(22): 2335-41.
45. Graham DJ. et al. Inddence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA 2004;292(21): 2585-90.
46. Smalley W et al. Contraindicated use of cisapride: impact of food and drug administration regulatory action. JAMA 2000;284(23): 3036-9.
47. Graham DJ. et al. Liver enzyme monitoring in patients treated with troglitazone. JAMA 2001;286(7):831-3.
48. Morrato EH, Staffa JA. Analysis of Longitudinal Claims Data to Examine First and Second-Line Use of Pemoline(CYLERT). In: International Society of Pharmacoeconomics and Outcomes Research 9th Annual International Meeting. 2004. Arlington, VA.
49. Rodriguez EM, Staffa JA, Graham DJ. The role of databases in drug postmarketing surveillance. Pharmacoepidemiol Drug Saf 2001;10(5):407-10.
50. Andrade SE, Graham DJ, Staffa JA. et al. Health plan administrative databases can efficiently identify serious myopathy and rhabdomyolysis J. Clin Epidemiol 2005;58(2):171-4.
51. World Health Organization and Report of CIOMS Working Group IV, Benefit-Risk Balance for Marketed Drugs:Evaluating Safety Signals. 1998: WHO Press.
52. Euopean Medicines Agency. Guideline on risk management systems for medicinal products for human use. 2005 [cited. April 30 2007]. Available at 〈www.emea.eu.int/pdfs/human/euleg/96268053en.pdf〉.
53. U.S. Food and Drug Administration. Guidance for Industry: Good pharmacovigilance practices and pharmacoepidemiologic assessment. 2005 March 2005 [cited April 7 2005]. Available at 〈http://www.fda.gov/cber/ guiddines.htm#pharma〉;.
54. U.S. Food and Drug Administration. Guidance for Industry: Premarketing risk assessment. 2005 March 2005 [cited April 7 2005]. Available at 〈http://wwwfda.gov/cder/guidance/6357thl.htm〉.
55. U.S. Food and Drug Administration. Guidance for Industry: Development and Use of Risk Minimization Action Plans. 2005 March 2005 [cited April 7 2005]. Available at 〈http://www.fda.gov/cber/guidelines.htm#minim〉.
56. U.S. Food and Drug Administration. FDA Issues Public Health Advisory on Vioxx as its Manufacturer Voluntarily Withdraws the Product. 2004 [cited April 30 2007]. Available at 〈http://www.fda.gov/bbs/topics/news/2004/ NEW01122.html〉.
57. Lo Re V, Strom BL. The role of academia and the research community in assisting the food and drug administration to ensure U.S. drug safety. Pharmacoepidemiol Drug Saf 2007;16(7):818-25.
58. Muir Gray JA. Evidence based policy making. BMJ 2004;329(7473):988-9.
59. van der Weyden M, Armstrong R. Evidence and Australian health policy: health policy decisions are based on more than evidence. MJA 2004;180(12):607-8.
60. Nutley S, Daview H, Walter I. Evidence Based Policy And Practice: Cross Sector Lessons from the UK. Queen Mary, University of London: ESRC UK Centre for Evidence Based Policy and Practice, 2002.
61. Merriam S. The case study in educational research: a review of selected literature. J Educ Thought 1985;19(3):204-17.
62. Sharp K. The case for case studies in nursing research: the problem of generalization. J Adv Nurs 1998;27:785-9.